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The coming of age of personalised therapies 
 
In the last decades the hottest areas of medical innovation have been the fields of targeted 
therapies and personalised medicine – medical treatments tailored to the specific molecular 
features of patients or diseases. Monoclonal antibodies are the prime example of successful 
targeted therapies, while genuinely personalised treatments have not been as forthcoming 
as expected. The greatest promise in this area comes from cellular and genetic therapies, 
which have the potential to be curative by stopping the causal chain leading to disease, or by 
regenerating cells or tissues that have genetic defects or have been damaged, or by 
enhancing bodily functions, like the immune system capacity to fight disease. This latter is 
the mechanism of action of CAR-T cells: the class of treatment that has recently been hailed 
as the coming of age for cellular therapies and advanced biological treatments in general. 
Until the summer of 2017, only a few advanced biological therapies had made it to the 
market and none has been a commercial success or has had a significant impact in terms of 
patients treated. In Europe, for instance, by the end of 2017 more than 500 clinical trials had 
led to only 18 marketing applications and 9 authorised products, 4 of which were later 
withdrawn from the market. All in all, 111 patients had been treated with those products. But 
when in 2017 the Food and Drugs Administration (FDA) in the USA licensed the first two 
CAR-T cell therapies (Kymriah and Yescarta) – followed by the European Medicines Agency 
in 2018 – observers thought that this was a turning point and that treatments with a clear 
potential for commercial success and medical impact had finally hit the market. While initially 
approved for the treatment of some forms of leukemia, it is expected that their therapeutic 
indications will expand and that new products will address an increasing range of tumours.  
 
However, advanced therapies like CAR-T cells bring new challenges for the regulation and 
financing of healthcare products. For instance, while CAR-T cells can save the life of 
patients not responding to other therapies, they also have severe side effects, so that both 
the FDA and the EMA have required risk-management plans and enhanced post-marketing 
surveillance. More strikingly, these products have hefty prices – in the USA Kymriah and 
Yescarta cost $475,000 and $373,000 respectively – which have triggered criticism and 
raised questions about rationing and financial sustainability.  
 
The new regulatory landscape and its critics 
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Both CAR-T cells products have achieved market authorisation on both sides of the Atlantic 
through some special regulatory pathways designed to assist companies with their 
development plans and to speed up the process of clinical evidence collection and 
regulatory review of the application. Both the FDA and the EMA have currently a portfolio of 
facilitated pathways: they are the result of an important change in the role and mission of 
these regulatory agencies. Traditionally, the goal of pharmaceutical regulations has been to 
ensure the safety, quality and effectiveness of the products that are authorised for 
commercialisation. But in the last decades, regulatory agencies have adopted a broader 
mission, which next to their traditional function includes facilitating faster and broader access 
to innovative products for patients with serious medical needs, as well as the promotion of 
medical innovation.  
 
This broader mission has important consequences. While before the vulnerable group they 
were protecting were patients receiving drugs, now they are also trying to help patients for 
which existing treatments are of no use or who may benefit from experimental drugs but may 
not wait until they achieve marketing authorisation. Remarkably, the new mission of 
promoting early access and innovation forces to rethink established regulatory practices: 
ensuring safety, quality and effectiveness is time-consuming and imposes high costs on 
developers, as such it delays market entry of innovative products and deters companies 
from developing products unless they have the potential for huge profits. Therefore, 
regulators have had to streamline the regulatory procedures and ease their requirements, in 
order to speed up the process and incentivise companies. The result is that the new 
regulatory focus on unmet medical needs creates trade-offs with the traditional values of 
safety, quality and effectiveness.  
 
Unsurprisingly, the new facilitated pathways designed to promote faster access and 
innovation have been subjected to a number of criticisms. The robustness of the evidence 
that is accepted by facilitated pathways has been questioned: smaller and shorter trials, and 
sometimes reliance on only one phase 2 trial – as in the case of the 2 CAR-T cells therapies 
– is not considered enough to establish effectiveness and detect less common adverse 
events. Similarly, the use of surrogate endpoints instead of meaningful clinical endpoints has 
led to the approval of drugs that were later shown to be ineffective. The safety of the process 
has also raised concerns. First, some studies have shown that strict review deadlines lead to 
decisions made under time pressure, which in turn are associated with higher incidence of 
post-marketing safety issues. Moreover, small trials on targeted populations provide limited 
information on the risks of wider use and thus make off-label use (notoriously difficult to 
discipline) rife with uncertainties and dangers. Another concern is the ability of these 
facilitated pathways to achieve their goals. Faster market authorisation does not immediately 
translate into faster or wider patients’ access. Even advocates of facilitated pathways have 
acknowledged that achieving their goals needs a broader system approach that involves 
Health Technology Assessment bodies, payers, providers and clinicians. Finally, scepticism 
has been manifested about the capacity of regulatory agencies to make up for higher 
uncertainty at time of approval with enhanced collection of post-marketing data. Critics have 
pointed out that so far compliance with the performance of post-marketing studies and the 
implementation of lifecycle evaluation have been poor, and that things are unlikely to change 
as long as industry lacks incentives and healthcare systems lack resources for their 
fulfilment.  
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The new vulnerable  
 
The new and extended mission of regulatory agencies in the medicinal domain is having 
significant impact on different vulnerable groups through reshuffling risks and benefits. 
Clearly, patients with serious unmet medical needs (i.e. not getting any really effective 
treatment for life threatening or severe diseases) are given much more attention than before, 
and arguably future patients could also benefit from the emphasis on innovation. For the 
target population addressed by new therapies there is a lower risk to miss their therapeutic 
benefits, but increased uncertainty about side-effects and durability of benefits. Future 
generations face a similar trade-off: they are likely to see more therapeutic options if 
facilitated pathways manage to promote innovation. However, not all innovation is valuable:  
unless ineffective products are removed from the market, they will increase the risk of poor 
therapeutic decisions and of mis-allocation of resources. Finally, new regulatory pathways 
redistribute risks between different patients’ groups. This is where they generate new 
vulnerable groups. Given that healthcare budgets cannot be indefinitely expanded, providing 
hyper-expensive therapies comes with the risk that public healthcare systems and private 
insurances will have to introduce coverage cuts elsewhere. This means that some patients 
will be at risk of losing (full) coverage of effective treatments. Furthermore, if the innovative 
and hyper-expensive treatments are introduced on the basis of less evidence about their 
effectiveness, then the allocation process will become less consistent and fair: a given level 
of uncertainty would be acceptable for some products, but not for others. In light of these 
impacts on different vulnerable groups, it seems that the benefits and the justifiability of 
facilitated regulatory pathways are conditional on regulators’ success in strengthen their 
capacity to acquire high-quality post-marketing evidence and withdraw from the market 
products that fail to confirm their value.   
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